
Annexon, Inc (ANNX) Stock Forecast & Price Target
Annexon, Inc (ANNX) Analyst Ratings
Bulls say
Annexon Inc. is poised for a positive outlook based on its clinical advancements and robust pipeline targeting complement-mediated disorders. The promising real-world evidence demonstrated by ANX005, showing a significant 10-point improvement in MRC sum score and enhanced health status in comparison to standard therapies, underlines the potential for breakthrough therapies within its portfolio. Additionally, the successful early completion of Phase 3 enrollment for ANX007 and its entry into the EMA's PRIME PDC pilot bolster the credibility of the company's innovative approach to vision preservation, further enhancing its competitive position in the biopharmaceutical sector.
Bears say
Annexon Inc faces significant risks that contribute to a negative outlook, particularly surrounding its lead product candidate, ANX005. The company's reliance on the successful completion of clinical studies, regulatory approval in both the US and EU, and the ability of ANX005 to meet peak commercial revenue expectations poses considerable uncertainties. Additionally, Annexon reported a substantial net loss of $49.2 million, reflecting ongoing financial challenges that may hinder its operational viability and strategic objectives.
This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.
Annexon, Inc (ANNX) Analyst Forecast & Price Prediction
Start investing in Annexon, Inc (ANNX)
Order type
Buy in
Order amount
Est. shares
0 shares